Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.

被引：3
|
作者：
Telli, Melinda L.
Litton, Jennifer Keating
Beck, Joseph Thaddeus
Jones, Jason M.
Andersen, Jay
Mina, Lida A.
Brig, Raymond
Danso, Michael A.
Yuan, Yuan
Symmans, William Fraser
Abbattista, Antonello
Noonan, Kay
Mata, Marielena
Laird, Douglas
Blum, Joanne Lorraine
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Highlands Oncol Grp, Springdale, AR USA
[4] Avera Canc Inst, Sioux Falls, SD USA
[5] West Canc Ctr, Compass Oncol, Tigard, OR USA
[6] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[7] Brig Ctr Canc Care & Survivorship, Knoxville, TN USA
[8] Virginia Oncol Associates, Norfolk, VA USA
[9] City Hope Comprehens Canc Ctr, Duarte, CA USA
[10] Beckman Res Inst, Duarte, CA USA
[11] Pfizer Oncol, Milan, Italy
[12] Pfizer Inc, Groton, CT 06340 USA
[13] Pfizer Inc, La Jolla, CA USA
[14] US Oncol Network, Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
554
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.
    Litton, Jennifer Keating
    Beck, Joseph Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Blum, Joanne Lorraine
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael A.
    Yuan, Yuan
    Abbattista, Antonello
    Noonan, Kay
    Chakrabarti, Jayeta
    Czibere, Akos
    Symmans, William Fraser
    Telli, Melinda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
    Telli, Melinda L.
    Litton, Jennifer K.
    Beck, J. Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael
    Yuan, Yuan
    Symmans, William F.
    Hopkins, Julia F.
    Albacker, Lee A.
    Abbattista, Antonello
    Noonan, Kay
    Mata, Marielena
    Laird, A. Douglas
    Blum, Joanne L.
    BREAST CANCER, 2024, 31 (05) : 886 - 897
  • [3] Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2-) advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA1/2) mutation
    Litton, Jennifer K.
    Laird, A. Douglas
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Martin, Miguel
    Roche, Henri
    Im, Young-Hyuck
    Goodwin, Annabel
    Blum, Joanne L.
    Eiermann, Wolfgang
    Chen, Ying
    Lanzalone, Silvana
    Chelliserry, Jijumon
    Czibere, Akos
    Albacker, Lee A.
    Frampton, Garrett M.
    Mina, Lida A.
    CANCER RESEARCH, 2020, 80 (16)
  • [4] Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
    Litton, Jennifer K.
    Beck, J. Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Blum, Joanne L.
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael
    Yuan, Yuan
    Abbattista, Antonello
    Noonan, Kay
    Niyazov, Alexander
    Chakrabarti, Jayeta
    Czibere, Akos
    Symmans, William F.
    Telli, Melinda L.
    ONCOLOGIST, 2023, 28 (10): : 845 - 855
  • [5] Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
    Blum, Joanne L.
    Laird, A. Douglas
    Litton, Jennifer K.
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Martin, Miguel
    Roche, Henri H.
    Lee, Kyung-Hun
    Goodwin, Annabel
    Chen, Ying
    Lanzalone, Silvana
    Chelliserry, Jijumon
    Czibere, Akos
    Hopkins, Julia F.
    Albacker, Lee A.
    Mina, Lida A.
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1383 - 1390
  • [6] Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study.
    Serrano Domingo, Juan Jose
    Cordero, David
    Menacho, Miriam
    Manuel del Rey, Jose
    Chamorro, Jesus
    Rosero, Diana I.
    Sotoca, Pilar
    del Campo, Laura
    Alonso, Gonzalo
    Saavedra Serrano, Cristina
    Fernandez-Abad, Maria
    Gion Cortes, Maria
    Guerra, Eva M.
    Martinez-Janez, Noelia
    Lopez-Miranda, Elena
    Vida Navas, Elena Maria
    Fuentes Mateos, Raquel
    Guillen Ponce, Carmen
    Teresa Salazar, Maria
    Cortes Salgado, Alfonso
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Awareness and availability of routine germline BRCA1/2 (gBRCA1/2) mutation testing in patients (pts) with advanced breast cancer (ABC) in Germany
    Lux, M. P.
    Decker, T.
    Runkel, E. D.
    Niyazov, A.
    Quek, R. G. W.
    Glastetter, E.
    Marschner, N. W.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S75 - S76
  • [8] Talazoparib (TALA) vs physician's choice of chemotherapy (PCT) in Asian patients (Pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA
    Lee, K-H.
    Kim, S-B.
    Sohn, J.
    Goodwin, A.
    Usari, T.
    Lanzalone, S.
    Im, Y-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial
    Litton, Jennifer K.
    Hurvitz, Sara A.
    Mina, Lida A.
    Rugo, Hope S.
    Lee, Kyung-Hun
    Goncalves, Anthony
    Diab, Sami
    Woodward, Natasha
    Goodwin, Annabel
    Yerushalmi, Rinat
    Roch, Henri
    Im, Young-Hyuck
    Eiermann, Wolfgang
    Quek, Ruben G.
    Usari, Tiziana
    Lanzalone, Silvana
    Czibere, Akos
    Blum, Joanne L.
    Martin, Miguel
    Ettl, Johannes
    CANCER RESEARCH, 2020, 80 (16)
  • [10] BRCA1 and BRCA2 germline mutational spectrum in Algerian triple negative breast cancer (TNBC) patients
    Cherbal, Farid
    Mehemmai, Chiraz
    Gaceb, Hadjer
    Mahfouf, Hassen
    Boualga, Kada
    CANCER RESEARCH, 2022, 82 (12)
12345